No grade  or higher neuropathy
Patients with grade  or higher peripheral neuropathy will be excluded in the dose escalation phase of the protocol
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients must not have grade  or higher peripheral neuropathy
ELIGIBILITY CRITERIA - PHASE II (ARM D): Patients must not have grade  or higher peripheral neuropathy
Patients with peripheral neuropathy of grade  or higher
Grade  or higher peripheral neuropathy at screening
Uncontrolled Grade  or higher infection
Active esophagitis grade B or higher
Patients with grade  or higher neuropathy
Patients must not have Grade  or higher peripheral neuropathy.
Grade  or higher pneumonitis
Grade  or higher peripheral neuropathy
No symptoms attributable to grade  or higher peripheral neuropathy
Patients with grade  or higher peripheral neuropathy are excluded
CTCAE grade  or higher peripheral neuropathy
Current grade  or higher peripheral neuropathy
Grade  or higher peripheral neuropathy.
More than one grade  or higher transaminase elevation
Patients with grade  or higher peripheral neuropathy
participants with Grade  or higher residual toxicities from prior therapy (including Grade  or higher peripheral neuropathy or any grade neuropathy with pain; excluding alopecia). This includes recovery from any major surgery. Note: Participants with planned surgical to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.
Grade  or higher persisting prior treatment-related neuropathy
Grade  or higher peripheral neuropathy
Paclitaxel arm: grade  or higher neuropathy
Grade  or higher peripheral neuropathy.
Grade  or higher peripheral neuropathy
Patients must not have grade  or higher peripheral neuropathy
Active Grade  or higher infection.
Patients who have had grade  or higher peripheral neuropathy within  days prior to registration are not eligible (must have resolved to grade  or lower to register)
Neuropathy grade  or higher
Grade  or higher peripheral neuropathy (paclitaxel arm only)
Grade  or higher neuropathy (CTCAE V.)
Subjects with T or higher, and N disease
Current grade II or higher peripheral neuropathy.
Significant peripheral neuropathy defined as grade  or higher
Current grade II or higher peripheral neuropathy.
Peripheral neuropathy that is grade  or higher
Grade  or higher peripheral neuropathy
Significant neurotoxicity/neuropathy (Grade  or higher) within  days prior to Day 
Grade  or higher neuropathy
Significant neurotoxicity/neuropathy (Grade  or higher) within  days prior to the first dose of study drug
Current grade  or higher neuropathy
Grade  or higher peripheral neuropathy
Grade  or higher peripheral neuropathy at the time of study entry
Grade  or higher peripheral neuropathy
Grade II or higher neuropathy
Significant neurotoxicity/neuropathy (Grade  or higher) within  days of first dose of study drug
